J Pathol Transl Med.  2022 Mar;56(2):113-114. 10.4132/jptm.2022.01.25.

What’s new in molecular genetic pathology 2022: immune checkpoint inhibitor biomarkers and select solid tumors

• Tsang PC
• Chen G

• KMID: 2527198
• DOI: http://doi.org/10.4132/jptm.2022.01.25

Abstract

Predictive biomarker testing plays a critical role in targeted immuno-oncology, including the use of immune checkpoint inhibitors (ICI) for various solid tumors. Molecular advancements in cancers of the breast, kidney and brain have continued to propel tumor classification and precision therapy.

Figure

• 

  Fig. 1. Esophagogastric adenocarcinoma. (A) H&E stain, 40 x. (B) PD-L1 22C3 immunostain demonstrating a combined positive score of close to 20% (positive: > 1%), indicating response to pembrolizumab.

• 

  Fig. 2. (A) Oligodendroglioma showing perinuclear clearing and delicate capillary network (H&E stain, 20 x). Co-deletion of 1p (B) and 19q (C) by dual color FISH. Target (orange) to control (green) signal ratio of ≤ 0.8 indicates loss of the target allele.

Reference

References

1. Bruford EA, Antonescu CR, Carroll AJ, et al. HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. Leukemia. 2021; 35:3040–3.

2. Shahbandi A, Nguyen HD, Jackson JG. TP53 mutations and outcomes in breast cancer: reading beyond the headlines. Trends Cancer. 2020; 6:98–110.

3. Henske EP, Cornejo KM, Wu CL. Renal Cell Carcinoma in tuberous sclerosis complex. Genes (Basel). 2021; 12:1585.

4. Price G, Bouras A, Hambardzumyan D, Hadjipanay- is CG. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma. EBioMedicine. 2021; 69:103453.